TNON Tenon Medical, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1560293 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY72.3%
TTM net income YoY-32.7%
TTM EPS YoY162.1%
Revenue 3-yr CAGR32.5%
Net income 3-yr CAGR—
Margins
Gross margin66.9%
Operating margin-225.9%
Net margin-305.1%
FCF margin-193.1%
EBITDA margin-220.7%
Returns
ROE-242.5%
ROA-128.0%
ROIC (approx.)-863.4%
Asset turnover0.42x
Leverage & solvency
Liabilities / assets43.1%
Debt / equity0.00x
Current ratio2.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.61x
Accruals ratio-50.2%
Payout ratio—
Capex / revenue7.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.43M | $1.28M | $1.38M | $1.48M | $1.17M | $564,000 | $726,000 | $770,000 |
| Cost of revenue | $482,000 | $465,000 | $434,000 | $464,000 | $400,000 | $319,000 | $403,000 | $417,000 |
| Gross profit | $950,000 | $814,000 | $945,000 | $1.02M | $773,000 | $245,000 | $323,000 | $353,000 |
| R&D expense | $804,000 | $768,000 | $662,000 | $527,000 | $428,000 | $503,000 | $691,000 | $569,000 |
| SG&A expense | $1.52M | $1.53M | $1.71M | $1.63M | $2.20M | $1.48M | $1.66M | $1.89M |
| Operating income | -$3.08M | -$3.35M | -$3.28M | -$2.87M | -$3.39M | -$2.86M | -$3.68M | -$3.17M |
| Interest expense | $719,000 | $852,000 | $176,000 | — | — | — | — | $0 |
| Net income | -$6.64M | -$4.05M | -$3.48M | -$2.83M | -$3.34M | -$2.77M | -$3.62M | -$3.09M |
| EBITDA | -$3.02M | -$3.31M | -$3.19M | -$2.77M | -$3.32M | -$2.81M | -$3.63M | -$3.06M |
| EPS (basic) | -5.39 | -12.35 | -0.31 | — | -14.17 | -12.76 | -1.01 | — |
| EPS (diluted) | -5.39 | -12.35 | 0.31 | — | -14.17 | -12.76 | 1.01 | — |
| Weighted avg. shares (diluted) | 1,231 | 328 | 11,268 | — | 236 | 217 | 3,597 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $8.27M | $1.68M | $4.61M | $3.76M | $3.44M | $7.85M | $10.31M | $6.54M |
| Receivables | $1.70M | $1.95M | $1.97M | $1.70M | $1.31M | $770,000 | $886,000 | $863,000 |
| Inventory | $882,000 | $783,000 | $806,000 | $1.05M | $1.36M | $688,000 | $607,000 | $606,000 |
| Current assets | $11.22M | $4.81M | $7.62M | $6.77M | $6.54M | $9.88M | $11.99M | $8.21M |
| PP&E, net | $717,000 | $771,000 | $901,000 | $918,000 | $663,000 | $842,000 | $698,000 | $752,000 |
| Goodwill | $2.41M | $2.41M | $2.41M | $2.41M | $2.41M | — | — | — |
| Intangibles | $441,000 | $455,000 | $470,000 | $485,000 | $500,000 | — | — | — |
| Total assets | $16.20M | $9.92M | $12.84M | $10.76M | $10.37M | $11.11M | $13.39M | $9.84M |
| Current liabilities | $3.83M | $8.30M | $7.41M | $3.21M | $3.04M | $2.56M | $2.19M | $1.87M |
| Total liabilities | $6.98M | $11.66M | $10.94M | $5.72M | $5.57M | $4.40M | $4.02M | $3.87M |
| Shareholders' equity | $9.22M | -$1.74M | $1.90M | $5.04M | $4.80M | $6.71M | $9.38M | $5.97M |
| Shares outstanding | 2.68M | 330,670 | 11.30M | 310,036 | 8.61M | 7.59M | 7.59M | 3.14M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.39M | -$2.76M | -$2.96M | -$2.22M | -$3.82M | -$2.21M | -$2.48M | -$2.78M |
| Capital expenditure | $8,000 | $172,000 | $56,000 | $192,000 | -$111,000 | — | — | -$37,000 |
| Free cash flow | -$2.40M | -$2.93M | -$3.02M | -$2.42M | -$3.71M | — | — | -$2.74M |
| Investing cash flow | -$8,000 | -$172,000 | -$56,000 | -$192,000 | -$639,000 | — | — | $37,000 |
| Financing cash flow | $8.99M | $0 | $3.87M | $2.73M | $59,000 | -$59,000 | $6.26M | $113,000 |
| Depreciation & amortization | $62,000 | $45,000 | $88,000 | $95,000 | $68,000 | $48,000 | $42,000 | $117,000 |
| Stock-based compensation | $120,000 | $412,000 | $331,000 | $344,000 | $58,000 | $417,000 | $872,000 | $883,000 |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.